Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Ziftomenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 317,847Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data
    Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data

    02 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/02/3092389/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Pivotal-Ziftomenib-Monotherapy-Data-at-2025-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    02 Jun 2025
    Share Share
    Kura Oncology and Kyowa Kirin's Ziftomenib NDA Accepted by FDA
    Kura Oncology and Kyowa Kirin's Ziftomenib NDA Accepted by FDA

    01 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/01/3091510/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Ziftomenib-in-Adults-with-Relapsed-or-Refractory-NPM1-Mutant-AML.html

    GLOBENEWSWIRE
    01 Jun 2025
    Share Share
    Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO
    Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO

    22 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/22/3087182/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-Pivotal-Monotherapy-Data-for-Ziftomenib-in-Oral-Presentation-at-the-2025-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    22 May 2025
    Share Share
    Kura Oncology and Kyowa Kirin Present Ziftomenib Data at 2025 EHA
    Kura Oncology and Kyowa Kirin Present Ziftomenib Data at 2025 EHA

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081280/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-Combination-Data-for-Ziftomenib-in-Oral-Presentation-at-the-2025-European-Hematology-Association-EHA-Congress.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share
    Kura Oncology Reports First Quarter 2025 Financial Results
    Kura Oncology Reports First Quarter 2025 Financial Results

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072827/35186/en/Kura-Oncology-Reports-First-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share
    Kura Oncology: First Patients Dosed in Ziftomenib Trial
    Kura Oncology: First Patients Dosed in Ziftomenib Trial

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069085/35186/en/Kura-Oncology-Announces-First-Patients-Dosed-in-Phase-1-Combination-Trial-of-Ziftomenib-for-the-Treatment-of-Advanced-GIST.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share